Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis.
about
Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosisPalivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosisPalivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosisPalivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosisPalivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosisHigh-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosisPalivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosisNeutrophil Extracellular Traps in Pulmonary Diseases: Too Much of a Good Thing?Lung infections associated with cystic fibrosis.Essential genome of Pseudomonas aeruginosa in cystic fibrosis sputum.Dornase alfa is well tolerated: data from the epidemiologic registry of cystic fibrosis.Clinical implications of inflammation in young children.The role of inhaled corticosteroids in the management of cystic fibrosis.Murine model for cystic fibrosis bone disease demonstrates osteopenia and sex-related differences in bone formation.Cystic fibrosis sputum DNA has NETosis characteristics and neutrophil extracellular trap release is regulated by macrophage migration-inhibitory factorRecombinant human deoxyribonuclease improves atelectasis in mechanically ventilated children with cardiac diseaseLack of neutrophil elastase reduces inflammation, mucus hypersecretion, and emphysema, but not mucus obstruction, in mice with cystic fibrosis-like lung disease.Bronchoscopy-derived correlates of lung injury following inhalational injuries: a prospective observational study.Free DNA in cystic fibrosis airway fluids correlates with airflow obstruction.Investigative bronchoprovocation and bronchoscopy in airway diseasesDNA and inflammatory mediators in bronchoalveolar lavage fluid from children with acute inhalational injuries.Anti-inflammatory therapies for cystic fibrosis-related lung disease.Antibiotic and anti-inflammatory therapies for cystic fibrosis.Review of recombinant human deoxyribonuclease (rhDNase) in the management of patients with cystic fibrosis.Targeting airway inflammation in cystic fibrosis in children: past, present, and future.Curbing inflammation in burn patients.Inflammation and its genesis in cystic fibrosis.Understanding the Entanglement: Neutrophil Extracellular Traps (NETs) in Cystic Fibrosis[Cystic fibrosis and associated complications].Implications of early inflammation and infection in cystic fibrosis: a review of new and potential interventions.Nonclassical pathway of Pseudomonas aeruginosa DNA-induced interleukin-8 secretion in cystic fibrosis airway epithelial cells.Abnormalities in the pulmonary innate immune system in cystic fibrosisInfectious risk factors and clinical indicators for tracheal mucus in British National Hunt racehorses.Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis.NET balancing: a problem in inflammatory lung diseases.Computed tomography reflects lower airway inflammation and tracks changes in early cystic fibrosis.Current understanding of the inflammatory process in cystic fibrosis: onset and etiology.Salt-independent abnormality of antimicrobial activity in cystic fibrosis airway surface fluid.Physiological basis of cystic fibrosis: a historical perspective.Impairment of apoptotic cell engulfment by pyocyanin, a toxic metabolite of Pseudomonas aeruginosa.
P2860
Q24194584-E9371078-08F8-4DB1-B0DB-F47E57DEC6E5Q24202211-49326277-294C-4CA4-AA30-E2D645D463BDQ24203706-CFE4C076-31E3-4AAB-8AFF-271840DE975BQ24240074-FC658184-2109-415E-A461-B97FFEAC00E5Q24240702-5FE588A8-233C-41DA-8BCE-03B51FA8B1B8Q24545304-B40FFDB2-AE00-43FF-970F-7E00D8326D1DQ26471040-4BFABAFB-435C-4A20-8346-3410FED8DDBCQ26738321-777B68C5-E90E-43DA-A58F-C166136A43F3Q30080000-D75481D1-BAE6-4439-BECF-3F6B925140E0Q30636019-5CADCF5E-73E6-4A18-94D4-A16CCD7E6915Q31122864-F190A0A0-3CF5-47E7-A9CC-E99B4A115A82Q33996589-5F20AE72-C041-4624-A24F-03861C757B76Q34131911-EC588A32-16D6-4580-8FC4-AA317007FAC7Q34359471-AE550B8B-A463-4E6F-987C-9B44BC88F79CQ34364117-90640CFC-AEF6-4C20-B5AF-B9B57A7C8669Q34381140-F4767ACD-5EAD-4210-A21B-D139A335778CQ34412599-1BE2392C-5399-4533-8CCB-D03E2F5A042AQ34731383-542C3CAA-5EB0-4D35-8050-FE163643214CQ35416114-EA31DAB7-5E21-4C19-B021-693F04A0ACBDQ36195439-E90A15E8-E62D-44F2-9E54-183D43C122DCQ36594975-60799411-34ED-45B3-8F34-F0FB656DFF0FQ37188760-C8CE5EFB-01C4-44B9-BCF4-A2A85B5A84B1Q37201467-04B1BB1A-8E9C-4F1B-A246-DA7DB1D21CEFQ37307836-4CC3D941-6AB0-48FA-8A9D-38265A19E554Q37866284-10C557AB-634E-4656-B893-BFB0E1384C0EQ38114093-D91A9EA0-A3B1-46BD-AE3D-CB8BADAA02C9Q38579962-FC8267C6-4C8F-4074-B473-E358E7768841Q39253846-69E28203-A51C-44B8-98C2-78F516D1F353Q41476517-4C3455C0-6BBA-4D70-8876-27DD078F8A90Q41591396-19719620-D22E-47C3-961E-AE6518658B66Q41945526-4EF7D84C-4BD9-46E9-AC9C-53145EA9DCD9Q42066758-0A55DF4C-B95E-401B-9F97-AB0C47CE755CQ42260157-AAD5752E-51FD-46B1-95E3-9B51682FDBBAQ42728646-3F847159-9B25-407E-8B5F-F84909C24189Q42947423-D96498B8-0680-4E7B-B7B3-4B93F05DD9D6Q44001744-CA54DB8A-E791-4AD2-B627-0DBB94A8765AQ44248066-257179F6-46D5-4DC8-B69D-93A045CEE871Q45878847-4DF01E8F-E8EC-4DA8-8C66-BE452104CBD5Q46380953-33D4DB8B-FBEF-42B6-B56B-3252B0743172Q46966094-E81313F1-A5E7-402F-90A9-28E2A6416224
P2860
Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Increased DNA levels in bronch ...... infants with cystic fibrosis.
@en
type
label
Increased DNA levels in bronch ...... infants with cystic fibrosis.
@en
prefLabel
Increased DNA levels in bronch ...... infants with cystic fibrosis.
@en
P2093
P1476
Increased DNA levels in bronch ...... infants with cystic fibrosis.
@en
P2093
Accurso FJ
Copenhaver SC
Kirchner KK
Wagener JS
P304
P356
10.1164/AJRCCM.154.5.8912759
P407
P577
1996-11-01T00:00:00Z